05:53 AM EDT, 04/30/2026 (MT Newswires) -- Berenberg raised its price target and earnings forecasts for Swedish Orphan Biovitrum (SOBI.ST), or Sobi, noting that the company remains one of its top stock picks in the medical technology/life sciences sector after an "excellent"start to 2026.

The price target was adjusted to 515 kronor from 500 kronor on Wednesday, while the buy recommendation on the stock was left unchanged.

"The stock offers 13% risk-adjusted growth from 2025-30, driven by multiple innovative drug launches, margin expansion, strong cash generation and insulation from geopolitical risk,"analysts said.

The research firm increased its sales growth forecasts by 2.8% for 2026 and 2% for 2027, while EPS projections were respectively lifted by 7.8% and 4.2%. For 2028, the estimates for both metrics were also upwardly revised.

"Investor appetite to discuss Sobi has increased notably since autumn 2025. We think that this reflects the company's strong performance and its larger market cap/liquidity, but also a growing appreciation for its attractive portfolio of innovative drugs and financial profile,"Berenberg said.